# Qure.ai Technologies Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qure-ai-technologies-private

- Industry: Healthcare IT
- Headquarters: Mumbai, India
- Website: www.qure.ai
- Total disclosed funding: $122M
- Latest round: Series D (Sep 25, 2024)
- Investors on record: 10

## About

Qure.ai Technologies Private Limited, based in India, develops AI-driven healthcare solutions that enhance diagnostic accuracy for critical conditions like lung cancer and tuberculosis, streamlining early detection and treatment processes. Founded in 2016 in Mumbai, India, Qure.ai Technologies Private Limited specializes in applying artificial intelligence to healthcare imaging. Founder and CEO Prashant Warier leads the company, which has raised a total of USD 65.00 mn across multiple funding rounds, the latest being Series D in September 2024. This round featured investments from 360 ONE Asset, HealthQuad, Kae Capital, Lightspeed Venture Partners, Merck Global Health Innovation Fund, and Novo Holdings, along with contributions from returning investor TEAMFund.Qure.ai specializes in artificial intelligence-driven healthcare solutions aimed at enhancing the early diagnosis and treatment of critical medical conditions, primarily focusing on lung cancer, tuberculosis (TB), and stroke. Their flagship products include qXR, which analyzes chest X-rays for abnormalities, and AI-enhanced tools for lung nodule management and stroke diagnostics. These technologies integrate seamlessly with both new and existing imaging equipment, facilitating immediate feedback for healthcare providers and expediting patient referrals for further testing. The company serves a diverse client base, including hospitals and imaging centers across multiple regions such as India, the UK, and Lesotho, with partnerships involving organizations like AstraZeneca and Medtronic. Qure.ai's initiatives, notably the EDISON Alliance’s 1 Billion Lives Challenge, aim to screen millions of patients by 2025, particularly in underserved communities. For the most recent year, 2023, Qure.ai reported revenues of USD 9.61 mn, with an EBITDA loss of USD 10.58 mn. The company's revenue model is based on business-to-business transactions through subscription agreements and partnerships, enabling healthcare providers to integrate Qure's technology into their systems for real-time imaging data analysis. In September 2024, Qure.ai Technologies Private Limited raised USD 65 mn in Series D funding, co-led by Lightspeed Venture Partners and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital. The funding will be utilized to enhance product development and further the company's foundational model. Qure.ai plans to expand its market reach, targeting new regions and sectors to bolster its AI-driven healthcare solutions.

## Funding rounds

- Series D, Sep 25, 2024, $65M — Lightspeed Venture Partners, Novo Holdings, Merck Global Health Innovation Fund, Kae Capital, 360 ONE, HealthQuad, TEAMFund
- Series D, May 22, 2024, $1.7M — Merck Global Health Innovation Fund
- Series C, Apr 13, 2022, $39M — Novo Holdings, MassMutual Ventures, HealthQuad
- Series B, Feb 24, 2020, $16M — Hong Shan, MassMutual Ventures, Red Wood Capital

## Investors

- Hong Shan — Series B
- MassMutual Ventures (https://capitalatlas.ai/funds/massmutual-ventures) — Series B, Series C
- Red Wood Capital (https://capitalatlas.ai/funds/red-wood-capital) — Series B
- Novo Holdings — Series C, Series D
- HealthQuad (https://capitalatlas.ai/funds/healthquad) — Series C, Series D
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series D
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series D
- Kae Capital (https://capitalatlas.ai/funds/kae-capital) — Series D
- 360 ONE (https://capitalatlas.ai/funds/360-one) — Series D
- TEAMFund — Series D